Last reviewed · How we verify
ISM®
At a glance
| Generic name | ISM® |
|---|---|
| Sponsor | Rovi Pharmaceuticals Laboratories |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Avapritinib Rollover Study (PHASE4)
- Non-interventional Study of Risperidone ISM® in Schizophrenia Patients Hospitalised Due to a Relapse
- Evaluation of IM Letrozole ISM® Pharmacokinetics, Safety, and Tolerability in Healthy Post-menopausal Women (LISA-1) (PHASE1)
- Pharmacokinetic, Safety, and Tolerability Study of Risperidone ISM® at Different Dose Strengths (PHASE1)
- Study to Evaluate the Efficacy and Safety of Risperidone ISM® in Patients With Acute Schizophrenia: Open Label Extension (PHASE3)
- Study to Evaluate the Efficacy and Safety of Risperidone in Situ Microparticle (ISM)® in Patients With Acute Schizophrenia (PHASE3)
- Comparative Bioavailability of Risperidone. (PHASE1)
- Comparative Bioavailability of Risperidone (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ISM® CI brief — competitive landscape report
- ISM® updates RSS · CI watch RSS
- Rovi Pharmaceuticals Laboratories portfolio CI